Deep Track reveals 12.3M Structure Therapeutics (NASDAQ: GPCR) stake

Rhea-AI Filing Summary

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 12,335,346 ordinary shares of Structure Therapeutics Inc., equal to 5.95% of the class as of December 31, 2025.

The ownership is calculated using 207,417,574 ordinary shares outstanding as of December 10, 2025, based on the issuer’s prospectus. The position includes 4,111,782 American Depositary Shares, each representing three ordinary shares. The filers certify the holdings are not for the purpose of changing or influencing control of the company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Structure Therapeutics Inc.

(Name of Issuer)

Ordinary Shares, $0.0001 par value

(Title of Class of Securities)

86366E106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 86366E106

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,335,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,335,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,335,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.95 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 86366E106

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,335,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,335,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,335,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.95 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 86366E106

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,335,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,335,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,335,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.95 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Structure Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 601 Gateway Blvd., Suite 900, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Ordinary Shares, $0.0001 par value
(e)	CUSIP No.: 86366E106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 12,335,346
(b)	Percent of class: 5.95%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 12,335,346
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 12,335,346
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	02/13/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	David Kroin
Name/Title:	David Kroin, Director
Date:	02/13/2026

David Kroin

Signature:	David Kroin
Name/Title:	David Kroin
Date:	02/13/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Ordinary Shares as of December 31,2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 207,417,574 Ordinary Shares outstanding as of December 10, 2025, according to the issuer's Prospectus filed with the SEC on December 10, 2025. Deep Track Capital LP, Deep Track Biotechnology Master Fund Ltd and David Kroin, together as the Reporting Persons', beneficially owns an aggregate of 12,335,346 ordinary shares of Structure Therapeutics Inc., consisting of 4,111,782 American Depositary Shares, each of which represents, and at the holder's option is convertible into, three ordinary shares JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 13, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

How many Structure Therapeutics (GPCR) shares does Deep Track beneficially own?

Deep Track and related reporting persons beneficially own 12,335,346 ordinary shares of Structure Therapeutics Inc. This stake is calculated using 207,417,574 ordinary shares outstanding as of December 10, 2025, as disclosed in the company’s prospectus referenced in the filing.

What percentage of Structure Therapeutics (GPCR) does Deep Track’s stake represent?

The filing states that Deep Track and the other reporting persons hold 5.95% of the outstanding ordinary shares of Structure Therapeutics Inc. This percentage is based on 207,417,574 ordinary shares outstanding as of December 10, 2025, as cited from the issuer’s prospectus.

Who are the reporting persons in the Structure Therapeutics (GPCR) Schedule 13G/A?

The reporting persons are Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. The filing identifies Deep Track Capital, LP and the Master Fund as the investment entities, with Kroin associated as Managing Member or Director, and jointly reporting the share ownership.

Is Deep Track seeking control of Structure Therapeutics (GPCR) with this 5.95% stake?

No. The certification explicitly states the securities were not acquired and are not held for the purpose of changing or influencing control of Structure Therapeutics Inc. The position is reported on a Schedule 13G/A, which is typically used for passive ownership.

How is Deep Track’s Structure Therapeutics (GPCR) position structured between ADS and ordinary shares?

The filing explains that the reporting persons’ aggregate 12,335,346 ordinary shares include 4,111,782 American Depositary Shares. Each ADS represents three ordinary shares, and at the holder’s option is convertible into those underlying Structure Therapeutics ordinary shares on that stated three-to-one basis.

What date does the Deep Track ownership information for Structure Therapeutics (GPCR) relate to?

The ownership information is reported as of December 31, 2025. The percentage calculation uses the issuer’s disclosure of 207,417,574 ordinary shares outstanding as of December 10, 2025, referenced from a prospectus filed with the SEC on that same December 10, 2025.